The Risk is Real. Calculate Your Risk Profile Here.
|HAC and VBP
|3.0% Total Medicare Base DRG *|
Request a Free Consultation
See firsthand how the ARROW® Advantage Program can protect your patients and the bottom line too.
1 Health Care-Associated Infections: A meta-analysis of Cost and Financial Impact on the US Health Care System; Eyal Zimlichman, MD, MSc; et al, JAMA Intern Med. 2013;173(22):2039-2046
Teleflex, Arrow, Arrowg+ard Blue Plus, Chlorag+ard and Never Settle are trademarks or registered trademarks of Teleflex Incorporated or its affiliates. ©2014 Teleflex Incorporated. All rights reserved.
Did you know more than 90% of hospitalized patients receive a vascular access device (VAD) and 50% of measured hospital-acquired conditions (HACs) are VAD related per pay-for-performance? Catheter-related infection is the most costly of HACs, requiring longer patient stays and an average $46,000 per patient in non-reimbursed expense.
Fortunately, now hospitals can draw the line. With ARROW® VADs featuring antithrombogenic and/or antimicrobial technology, you can help improve patient outcomes, lower costs, improve efciency and reduce vascular access-related complications.
ARROW® Vascular Access Devices Protect Your Patients And The Bottom Line Too.